Akynzeo FDA Approval History
FDA Approved: Yes (First approved October 10, 2014)
Brand name: Akynzeo
Generic name: netupitant and palonosetron
Dosage form: Capsules
Company: Helsinn Healthcare SA
Treatment for: Nausea/Vomiting, Chemotherapy Induced
Akynzeo (netupitant and palonosetron) is a substance P/neurokinin 1 (NK1) receptor antagonist and serotonin-3 (5-HT3) receptor antagonist fixed-dose combination indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).
Development timeline for Akynzeo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.